Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
Q1 2023 vs. Q4 2022
How the institutions holding Alvotech changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 11 | 17 | +6 |
| Shares | 18.7M | 19.0M | +208.1K (+1.1%) |
| Value | $184.7M | $244.6M | +$59.9M (+32.4%) |
New holders (7)
Institutions that held Alvotech at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Littlejohn & Co LLC | 1,132,391 | $14.6M | 8.87% |
| Invesco Ltd. | 146,350 | $1.89M | 0.00% |
| Geode Capital Management, LLC | 34,007 | $438.7K | 0.00% |
| Mariner, LLC | 18,974 | $245.0K | 0.00% |
| Bank of America Corp | 15,140 | $195.3K | 0.00% |
| Wolverine Asset Management LLC | 2,376 | $30.6K | 0.00% |
| JPMorgan Chase & Co | 499 | $6.00K | 0.00% |
Sold out (1)
Institutions that held Alvotech at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Gamco Investors, Inc. Et Al | 13,447 | $134.5K |